应用德尔菲法构建抗肿瘤药物临床使用合理性评价指标体系

Establishment of the indicator system for clinical rationality evaluation of antitumor drugs by the Delphi method

目的:建立抗肿瘤药物临床使用合理性评价指标体系,为开展抗肿瘤药物临床使用合理性评价提供参考。方法:应用德尔菲法,对30名与抗肿瘤药物使用和评价工作相关的专家进行两轮调查,基于专家对抗肿瘤药物使用合理性评价指标的评分建立评价指标体系。结果:两轮专家咨询的问卷回收率分别为90%和96.30%,说明专家的积极性较高;权威系数分别为0.83和0.86,反映了专家的权威性高;一级指标的协调系数为0.310(P<0.001);二级指标的协调系数为0.142(P<0.001),专家对全部指标的总体协调性较好,调查结果可取。最终建立了包含7个一级指标和17个二级指标的抗肿瘤药物临床使用合理性评价指标体系。结论:本研究所选专家权威性高、代表性强,并且专家对项目意见具有较好的一致性,故该评价体系可靠程度较高。

Objective:To establish the indicator system for clinical rationality evaluation of antitumor drugs,so as to provide reference for the evaluation of clinical rationality of antitumor drugs.Methods:Two rounds of consultations were performed on 30 experts corresponding to the use and evaluation of antitumor drugs by the Delphi method,and then the indicator evaluation system was developed based on the evaluation results and scores of the indicators.Results:The recovery rates of two rounds of questionnaires forms were respectively 90%and 96.30%,indicating high enthusiasm of experts.The authoritative coefficients were respectively 0.83 and 0.86,indicating high authority of the experts.The coordination coefficients of the first-level and second-level indicators were sequentially 0.310(P<0.001)and 0.142(P<0.001),reflecting that the overall coordination of the experts concerning the evaluation indicators was good and the obtained results were eligible.Finally,an indicator system for clinical rationality evaluation of antitumor drugs was established,which included 7 first-level indicators and 17 second-level indicators.Conclusion:Our study indicates that the selected experts are highly authoritative and their opinions on the subject are relatively consistent.Therefore,the indicator evaluation system is quite reliable.